Immune Control combines two clinically researched probiotic strains specifically selected for their ability to regulate immune activity and support individuals with elevated histamine responses. This targeted probiotic approach moves beyond general gut health supplements to provide condition-specific therapeutic support for allergic sensitivities, immune dysfunction, and histamine-related conditions.

Lactobacillus rhamnosus LGG (Lactobacillus rhamnosus GG) works as a powerful mast cell stabilizer, directly addressing one of the key drivers of histamine release and allergic reactions [16]. LGG reinforces gut barrier integrity by tightening epithelial junctions, reducing antigen leakage, and decreasing the immune triggers that normally activate mast cells. It amplifies immune tolerance by increasing IL-10 and expanding regulatory T-cell (Treg) populations, which directly suppress IgE-driven pathways. Clinical research demonstrates that LGG shows robust improvements in structural barrier integrity, including reductions in zonulin of 15-40 percent, decreases in endotoxin (LPS) by 20-50 percent, and improvements in lactulose–mannitol permeability tests by approximately 15-45 percent [16].

The strain also provides comprehensive support for autoimmune and inflammatory conditions. In a 12-month double-blind randomised trial for rheumatoid arthritis, patients receiving LGG reported a 71% improvement in disease activity compared with 30% in the control group [9]. For inflammatory bowel conditions, LGG demonstrated remarkable efficacy - in children with mild to moderate Crohn's disease, taking 20 billion CFU for six months resulted in a 73% reduction in Crohn's Disease Activity within just four weeks [37]. For ulcerative colitis, 85% of patients receiving LGG alone remained in remission over 12 months, matching the effectiveness of standard pharmaceutical therapy [37].

Lactobacillus paracasei LP-33 complements LGG through its direct action on the gut-immune axis, specifically targeting allergic sensitivities and histamine production. LP-33 interacts with gut-associated lymphoid tissue (GALT) to rebalance helper-T cell activity, suppressing key Th2 cytokines including IL-4, IL-5, and IL-13, which drive eosinophilic inflammation, IgE production, and allergic sensitisation [16]. This dual action reduces serum IgE levels, inhibits mast-cell degranulation, and lowers histamine release, clinically translating to reduced reactivity in allergic and atopic conditions. In a randomized controlled trial involving 425 adults with persistent allergic rhinitis due to grass pollen, LP-33 showed significant improvement in Rhinitis Quality of Life scores, with notable reductions in ocular symptoms when used alongside antihistamines [37]. A separate study with 90 adults suffering from house-dust mite allergy found that LP-33 group experienced a significant reduction in overall symptom scores, while the placebo group reported increased symptoms and discomfort [16].

Together, LP-33 and LGG promote a coordinated shift toward a Th1/Treg-dominant immune profile, reduce Th2-associated allergic signalling, lower IgE sensitivity, and support balanced, resilient immune function. This combination proves beneficial for allergies, eczema, gut inflammation, autoimmunity and barrier dysfunction. The strains work synergistically - LGG provides direct structural tightening of the gut barrier, while LP-33 provides immune stabilisation that prevents ongoing barrier disruption, making this combination particularly effective for individuals with intestinal permeability, allergy-linked gut inflammation, or immune-mediated mucosal dysfunction [16].